

Fapon Biotech is pleased to confirm the effective detection of its COVID-19 antibodies to the mainstream variants, B.1.1.7 (also known as SARS-CoV-2 VUI 202012/01) and B.1.351 (known as 501Y.V2) after implemented evaluation using recombinant NP antigens.

The evaluations showed the same reaction to wild-type strains, confirming the effective detection to COVID-19 variants and wild-type strains with no omission in test results.

Fapon Biotech has a strong position in the fight of COVID-19. Its antibody pairs have the **best-in-class specificity**, which had been **widely used by global reagent manufacturers** to manufacture hundreds of millions of antigen test kits.

Studies and monitoring of COVID-19 had been deployed intensively by healthcare official authorities. To support these programs, Fapon Biotech leverages on the abilities of variant strain detection, launches service to help the verification of detection efficacy of B.1.1.7 & B.1.351 variants in test kits. IVD Reagent Manufacturers are welcome to contact market@fapon.com for the sign up of test kit verification service.

Best Seller, Antibody Pairs for COVID-19 Ag test

Antibody Pairs	Catalog No.	Source	Clone	Isotype	Application	Platform
Pair 1	FPZ0574	Mouse	8F5	IgG	Conjugate	Colloidal Gold/ Immunofluorescence/ CLIA
	FPZ0546	Mouse	5E7	lgG1	Coating	
Pair 2	FPZ0573	Mouse	8A8	IgG	Conjugate	
	FPZ0546	Mouse	5E7	lgG1	Coating	



